We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-20.8%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$279M
AUM Growth
+$40.4M
Cap. Flow
+$105M
Cap. Flow %
37.71%
Top 10 Hldgs %
65.76%
Holding
38
New
13
Increased
10
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$18.6M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$12.9M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$11.3M
4
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$8.56M
5
CMRX
Chimerix, Inc.
CMRX
+$8.49M

Top Sells

Rank Stock Value
1
TTHI
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
+$1.65M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$765K
3
LSTA icon
Lisata Therapeutics
LSTA
+$353K

Sector Composition

Rank Sector Weight
1 Healthcare 68.66%
2 Technology 3.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TENX icon
26
Tenax Therapeutics
TENX
$363M
$2.27M 0.82%
35
– –
RXDX
27
DELISTED
Ignyta, Inc.
RXDX
$1.94M 0.7%
+287,173
New +$2.36M
LSTA icon
28
Lisata Therapeutics
LSTA
$9.02M
$1.28M 0.46%
11,404
-3,588
-24% -$353K
PTLA
29
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.02M 0.37%
+50,000
New +$1.59M
PTLA
30
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$598K 0.21%
+29,300
New +$930K
RIGL icon
31
Rigel Pharmaceuticals
RIGL
$681M
$328K 0.12%
+15,787
New +$389K
STRM
32
DELISTED
Streamline Health Solutions
STRM
$214K 0.08%
10,107
– –
ATYR
33
aTyr Pharma
ATYR
$47.6M
$197K 0.07%
+3,565
New +$271K
CYTK icon
34
PUT
Cytokinetics
CYTK
$10.5B
– –
-106,800
Closed -$1.12M
MNKD icon
35
PUT
MannKind Corp
MNKD
$1.21B
– –
-100,600
Closed -$729K
FLXN
36
CALL
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-78,100
Closed -$1.5M
GWPH
37
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-100,000
Closed -$6.94M
TTHI
38
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
– –
-856,602
Closed -$1.65M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2016 Portfolio in Review

As of Q1 2016, Great Point Partners held 38 positions worth $279M, up 17% from $238M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Great Point Partners deployed $105M of net new capital in Q1 2016, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was bluebird bio: 30,350 shares worth $16.7M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 58% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Paratek Pharmaceuticals, Inc., an estimated $765K trimmed.

  • Great Point Partners's largest Q1 2016 buy was bluebird bio: 30,350 shares worth $16.7M.
  • Great Point Partners added most to Adamas Pharmaceuticals in Q1 2016, an estimated $11.3M increase.
  • Great Point Partners's biggest Q1 2016 reduction was Paratek Pharmaceuticals, Inc., cutting an estimated $765K.
  • Great Point Partners fully exited TRANSITION THERAPEUTICS INC (CANADA) in Q1 2016, selling an estimated $1.65M.
  • Great Point Partners's ten largest holdings make up 66% of its $279M portfolio in Q1 2016.
  • Great Point Partners opened 13 new positions and closed 5 in Q1 2016.
  • Great Point Partners's portfolio value rose 17% quarter-over-quarter to $279M.

Based on Great Point Partners's 13F filing for Q1 2016, filed 16 May 2016.